Show simple item record

dc.contributor.authorClamp, Andrew R
dc.contributor.authorMäenpää, J
dc.contributor.authorCruickshank, D
dc.contributor.authorLedermann, J A
dc.contributor.authorWilkinson, Peter M
dc.contributor.authorWelch, Richard
dc.contributor.authorChan, S
dc.contributor.authorVasey, Paul
dc.contributor.authorSorbe, B
dc.contributor.authorHindley, A
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2009-07-07T15:49:01Z
dc.date.available2009-07-07T15:49:01Z
dc.date.issued2006-01-16
dc.identifier.citationSCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. 2006, 94 (1):55-61 Br. J. Canceren
dc.identifier.issn0007-0920
dc.identifier.pmid16404360
dc.identifier.doi10.1038/sj.bjc.6602910
dc.identifier.urihttp://hdl.handle.net/10541/72865
dc.description.abstractThe feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m(-2) (arm A, n=51) or docetaxel 60 mg m(-2) with irinotecan 200 mg m(-2) (arm B, n=49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58-81%; P=0.079; arm B 67% (90% CI 55-78%; P=0.184)). Median-dose intensities were >85% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients, respectively, withdrew owing to treatment-related toxicity. Grade 3-4 sensory neurotoxicity was more common in arm A (1.9 vs 0%) and grade 3-4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted.
dc.language.isoenen
dc.subjectFallopian Tube Canceren
dc.subjectOvarian Canceren
dc.subjectPeritoneal Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshArea Under Curve
dc.subject.meshCamptothecin
dc.subject.meshCarboplatin
dc.subject.meshCarcinoma
dc.subject.meshDisease Progression
dc.subject.meshDrug Administration Schedule
dc.subject.meshFallopian Tube Neoplasms
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfusions, Intravenous
dc.subject.meshMiddle Aged
dc.subject.meshOvarian Neoplasms
dc.subject.meshPeritoneal Neoplasms
dc.subject.meshSurvival Analysis
dc.subject.meshTaxoids
dc.subject.meshTreatment Outcome
dc.titleSCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThe feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m(-2) (arm A, n=51) or docetaxel 60 mg m(-2) with irinotecan 200 mg m(-2) (arm B, n=49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58-81%; P=0.079; arm B 67% (90% CI 55-78%; P=0.184)). Median-dose intensities were >85% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients, respectively, withdrew owing to treatment-related toxicity. Grade 3-4 sensory neurotoxicity was more common in arm A (1.9 vs 0%) and grade 3-4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted.


This item appears in the following Collection(s)

Show simple item record